GlassScriptPhysician profile
Luanne Hespeler
NPI 1366527822
$7,083.71
in general payments reported to CMS, 2019-2025
25 companies · $24.17 in 2025
The $24.17 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,590 · 2022: $2,168 · 2023: $1,835 · 2024: $1,466 · 2025: $24.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,211 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,211.16 |
| Education | $114.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,146.46 | 2021-2024 | |
| Pfizer INC. | $799.75 | 2021-2024 | |
| Janssen Biotech, INC. | $644.41 | 2021-2024 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $567.22 | 2021-2024 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $464.20 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $384.50 | 2021-2024 | |
| Ucb, INC. | $359.44 | 2022-2024 | Bimzelx, Cimzia |
| Amgen INC. | $346.38 | 2021-2024 | Otezla |
| Leo Pharma INC. | $342.76 | 2021-2024 | Adbry |
| Lilly USA, LLC | $298.78 | 2021-2023 | Taltz, Olumiant |
| Merz North America, INC. | $291.68 | 2023 | |
| Incyte Corporation | $247.83 | 2022-2023 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $232.52 | 2021-2023 | Jublia |
| Sun Pharmaceutical Industries INC. | $227.30 | 2021-2024 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $151.35 | 2022-2024 | Sotyktu |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $125.73 | 2022-2024 | |
| Genzyme Corporation | $104.44 | 2021-2023 | |
| Verrica Pharmaceuticals INC. | $66.73 | 2023-2024 | Ycanth |
| Biofrontera INC. | $61.57 | 2021-2025 | Bf-Rhodoled, Rhodoled Xl, Ameluz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.95 | 2023-2024 | Spevigo |
| Helsinn Therapeutics (U.S.), INC. | $41.87 | 2021 | |
| Almirall LLC | $40.17 | 2021-2024 | Klisyri |
| Epi Health, LLC | $33.60 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $24.71 | 2023 | |
| Arcutis Biotherapeutics, INC. | $19.36 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luanne Hespeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.